Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
A Phase II Study of Tailored Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endormetrial Cancer (RAINBO BLUE & TAPER)
Sponsor: Canadian Cancer Clinical Trials Network
This observational or N/A phase trial investigates Endometrial Cancer and is currently actively recruiting participants. Canadian Cancer Clinical Trials Network leads this study, which shows 30 recorded versions since 2022 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Study Description(click to expand)This study is being done in order to find out if this new approach is better or worse than the usual approach for early-stage endometrial cancer. The usual approach is defined as the care most people get for early-stage endometrial cancer.
The usual approach for patients who are not in a study is treatment with surgery. Tissue that is removed as part of this procedure is analyzed in the pathology laboratory to guide the doctor to decide whether or not additional treatment such as radiation and or chemotherapy should be recommended.
This study is being done in order to find out if this new approach is better or worse than the usual approach for early-stage endometrial cancer. The usual approach is defined as the care most people get for early-stage endometrial cancer.
The usual approach for patients who are not in a study is treatment with surgery. Tissue that is removed as part of this procedure is analyzed in the pathology laboratory to guide the doctor to decide whether or not additional treatment such as radiation and or chemotherapy should be recommended.
Status Flow
Change History
30 versions recorded-
Apr 16, 2026 — Present [daily]
Recruiting
Phase: PHASE2 → None
-
Mar 2026 — Apr 2026 [monthly]
Recruiting PHASE2
-
Feb 2026 — Mar 2026 [monthly]
Recruiting PHASE2
-
Jan 2026 — Feb 2026 [monthly]
Recruiting PHASE2
-
Dec 2025 — Jan 2026 [monthly]
Recruiting PHASE2
▶ Show 25 earlier versions
-
Nov 2025 — Dec 2025 [monthly]
Recruiting PHASE2
-
Oct 2025 — Nov 2025 [monthly]
Recruiting PHASE2
-
Sep 2025 — Oct 2025 [monthly]
Recruiting PHASE2
-
Jul 2025 — Sep 2025 [monthly]
Recruiting PHASE2
-
Jun 2025 — Jul 2025 [monthly]
Recruiting PHASE2
-
May 2025 — Jun 2025 [monthly]
Recruiting PHASE2
-
Apr 2025 — May 2025 [monthly]
Recruiting PHASE2
-
Feb 2025 — Apr 2025 [monthly]
Recruiting PHASE2
-
Jan 2025 — Feb 2025 [monthly]
Recruiting PHASE2
-
Dec 2024 — Jan 2025 [monthly]
Recruiting PHASE2
-
Nov 2024 — Dec 2024 [monthly]
Recruiting PHASE2
-
Sep 2024 — Nov 2024 [monthly]
Recruiting PHASE2
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE2
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE2
-
Apr 2024 — Jun 2024 [monthly]
Recruiting PHASE2
-
Mar 2024 — Apr 2024 [monthly]
Recruiting PHASE2
-
Jan 2024 — Mar 2024 [monthly]
Recruiting PHASE2
-
Dec 2023 — Jan 2024 [monthly]
Recruiting PHASE2
-
Nov 2023 — Dec 2023 [monthly]
Recruiting PHASE2
-
Aug 2023 — Nov 2023 [monthly]
Recruiting PHASE2
-
Jul 2023 — Aug 2023 [monthly]
Recruiting PHASE2
-
May 2023 — Jul 2023 [monthly]
Recruiting PHASE2
-
Apr 2023 — May 2023 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jan 2023 — Apr 2023 [monthly]
Not Yet Recruiting PHASE2
First recorded
Dec 2022
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
This protocol tests de-escalated adjuvant treatment in patients with POLE-mutated or p53wt/NSMP (p53 wildtype/no specific molecular profile) early-stage endometrial cancer (EC). Patients may be enrolled in one of two sub-studies * EN10.A/RAINBO BLUE: POLE-mutated EC * EN10.B/TAPER: p53 wildtype / NSMP EC
Contact Information
- Canadian Cancer Clinical Trials Network
- Canadian Cancer Trials Group
For direct contact, visit the study record on ClinicalTrials.gov .